For example, Atezolizumab (TecentriqTM, MPDL3280A) as PD-L1/PD-1 immune checkpoint inhibitor, was approved as a second-line therapy for advanced bladder cancer in 2016 [23, 24]. This evidence concerns the gene CD274 and urinary bladder carcinoma.